FTC Seeks Public Comment on Aurobindo-Lannett Merger Settlement Requiring Drug Product Divestitures
June 25, 2026
June 25, 2026
WASHINGTON, June 25 (TNSFR) -- The Federal Trade Commission has proposed a settlement requiring pharmaceutical companies Aurobindo, Hyderabad, India, and Lannett, Trevose, U.S., to divest four generic drug products to preserve market competition following their planned merger.
The FTC announced on June 23 that it had accepted, subject to final approval, a consent agreement addressing antitrust concerns arising from Aurobindo Pharma Limited's proposed acquisition of Lannett Comp . . .
The FTC announced on June 23 that it had accepted, subject to final approval, a consent agreement addressing antitrust concerns arising from Aurobindo Pharma Limited's proposed acquisition of Lannett Comp . . .